|

| 产地 | France |
| 品牌 | AntibodySystem |
| 货号 | YHB27201 |
| 用途 | 仅用于科研 |
| 包装规格 | 100 μg |
| 纯度 | 0.95% |
| CAS编号 | |
| 是否进口 | 否 |
| 货号 | YHB27201 |
| 产品名称 | Recombinant Human UPK3A Protein, N-His |
| 规格 | 100 μg |
| 价格 | 1880 |
| 状态 | Lyophilized |
| 储存缓冲液 | Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol. |
| 纯度 | >90% as determined by SDS-PAGE. |
| 应用 | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| 内毒水平 | Please contact with the lab for this information. |
| 表达系统 | E. coli |
| Accession | O75631 |
| 蛋白长度 | Phe15-Ile211 |
| 预测分子量 | 23.54 kDa |
| 稳定性与储存条件 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 重悬 | Reconstitute in sterile water for a stock solution. |
| 别名 | Uroplakin-3a, UPK3A, UP3a, UPK3, UPIII, Uroplakin III |
| 物种 | Homo sapiens (Human) |
| 运输 | In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise. |
| 备注 | For research use only. |
UPK3A(尿斑蛋白3A)属于泌尿上皮跨膜结构蛋白,构成膀胱上皮屏障结构,维持黏膜延展性、阻拦微生物附着,主要表达于尿路上皮细胞表层。蛋白表达异常会破坏尿路屏障完整性,还可作为尿路异常标志物,是泌尿上皮屏障构建、尿路异常筛查方向常用研究靶点。
Q1:UPK3A 重组蛋白核心参数是什么?
A:大肠杆菌表达、N 端 His 标签,理论分子量 23.54 kDa,SDS-PAGE 检测纯度>90%。
Q2:冻干蛋白该如何复溶配制母液?
A:使用无菌纯水复溶制备储备液,详细操作步骤参照产品配套说明书。
Q3:正确储存方式与保质期时长?
A:频繁取用可 2~8℃存放,长期分装置于 - 20~-80℃保存,有效期 12 个月,切勿反复冻融。
Q4:蛋白适用实验以及使用禁忌?
A:可开展 WB、ELISA、免疫原制备实验,生物活性尚在验证,仅用于科研场景使用。
前沿相关研究:
1.Multimodal prognostic models for bladder urothelial carcinoma: uroplakin III combined with serum and demographic data. PMID: 41049846.
2.TROP2 expression is associated with early stage and favorable prognosis in upper tract urothelial carcinoma. PMID: 41686301.
3.Genomic Risk Factors for Urethral Stricture: A Systematic Review and Gene Network Analysis.PMID: 38160764.
4.Urothelial protein expression in pediatric patients with ureteropelvic junction obstruction. PMID: 42429969.
5.Genetics of kidney disorders in Phelan-McDermid syndrome: evidence from 357 registry participants.PMID: 37733098.
6.RPL29 as a radiotherapy-sensitive prognostic biomarker in multiple myeloma. PMID: 41199244.
7.Molecular characterization of non-muscle invasive tumor from N-methyl-N-nitrosourea (MNU)-induced urothelial carcinoma in a rat model reveals hallmarks of both luminal and basal subtypes.PMID:41666762.